Sponsor content

One-shot gene silencing therapy for chronic and life-threatening conditions

Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA. To download the full article, please sign in.

Go to the profile of Benitec Biopharma Ltd
Nov 05, 2015
1
Page of
Go to the profile of Benitec Biopharma Ltd

Benitec Biopharma Ltd

Benitec Biopharma was founded in 1997 and has been publicly listed on the ASX since then. During the mid 2000's, Benitec was involved in a lengthy and ultimately successful patent litigation, which included defense of our platform technology patents. This action resulted in their being re-examined and re-issued in all jurisdictions by 2012. Benitec Biopharma is developing therapeutic agents in-house for use with human conditions of high prevalence and value. In addition, we out-license our proprietary technology to biotechnology and biopharma companies for use in non-core therapeutic areas, such as HIV/AIDS, Retinitis Pigmentosa, Huntington's Disease, and human cancer vaccines. We also licence the technology as a research agent and cross-license in other situations.

Comments are disabled